RxDoctor Payments Data

Daniel Reyes-Villa, MD

Family Medicine · San Jose, CANPI 1013136563

Payments from drug & device makers

$5,995in general payments, 2019–2025

Across 165 payments — averaging $36.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Johnson & Johnson$975
  • Amgen$613
  • Pfizer$398
  • Novo Nordisk$332
  • Bayer$315
  • plus $1K from 10 others

What the payments were for

  • Food & beverage$5,995100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,995 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$30,526
Medicare patients
84
Services billed
189

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol90$98,428
JardianceEmpagliflozin59$70,896
EliquisApixaban67$69,076
JanuviaSitagliptin Phosphate42$51,021
OzempicSemaglutide34$49,485
RybelsusSemaglutide21$47,853
XareltoRivaroxaban16$25,321
EntrestoSacubitril/Valsartan16$20,706
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$14,138
Atorvastatin Calcium592$7,864
InvokanaCanagliflozin12$6,725
CreonLipase/Protease/Amylase12$6,400
RestasisCyclosporine11$6,024
Fluticasone Propionate HfaFluticasone Propionate17$5,118
Gabapentin201$3,940

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$2,012$98,42890 claims
Novo NordiskOzempic, Rybelsus$332$97,33855 claims
Boehringer IngelheimJardiance$171$70,89659 claims
PfizerEliquis$398$69,07667 claims
MerckJanuvia$238$51,02142 claims
Johnson & JohnsonXarelto, Invokana$975$32,04728 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →